The abstract is read at the publisher; the summary is JClub's.
Tambotatug pelitecan improved overall survival versus topotecan in relapsed extensive-stage small-cell lung cancer after first-line platinum therapy, with median 13.3 vs 9.4 months and HR 0.46.
- Why it matters: After progression on platinum-based therapy, outcomes in relapsed small-cell lung cancer remain poor, and better post-platinum options are needed.
- What they did: In a phase 3, multicenter, open-label randomized trial, 451 patients were assigned 1:1 to tambotatug pelitecan or topotecan; interim analysis assessed overall survival, progression-free survival, and investigator-assessed response.
- The result: Tambotatug pelitecan also increased progression-free survival (7.4 vs 2.8 months), confirmed objective response (59.1% vs 9.7%), and reduced grade 3+ adverse events (55.4% vs 77.9%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.